Alpha Cognition Inc. Common Stock (ACOG)

CA — Financial Services Sector
Peers:

Automate Your Wheel Strategy on ACOG

With Tiblio's Option Bot, you can configure your own wheel strategy including ACOG - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ACOG
  • Rev/Share 0.1828
  • Book/Share 2.5476
  • PB 3.4307
  • Debt/Equity 0.0
  • CurrentRatio 17.1401
  • ROIC -0.228

 

  • MktCap 135743562.0
  • FreeCF/Share -0.4602
  • PFCF -18.414
  • PE -14.533
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -0.4943

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation ACOG H.C. Wainwright -- Buy -- $20 March 18, 2025

News

What Makes Alpha Cognition Inc. (ACOG) a New Strong Buy Stock
ACOG
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive

Alpha Cognition Inc. (ACOG) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read More
image for news What Makes Alpha Cognition Inc. (ACOG) a New Strong Buy Stock
Is Alpha Cognition Inc. (ACOG) Outperforming Other Medical Stocks This Year?
ACOG
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Here is how Alpha Cognition Inc. (ACOG) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.

Read More
image for news Is Alpha Cognition Inc. (ACOG) Outperforming Other Medical Stocks This Year?
Should You Buy Alpha Cognition Inc. (ACOG) After Golden Cross?
ACOG
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive

Alpha Cognition Inc. (ACOG) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ACOG's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Read More
image for news Should You Buy Alpha Cognition Inc. (ACOG) After Golden Cross?
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025
ACOG
Published: May 19, 2025 by: Newsfile Corp
Sentiment: Neutral

Dallas, Texas--(Newsfile Corp. - May 19, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition began 2025 by launching ZUNVEYL(R) (benzgalantamine) to the U.S. long-term care (LTC) market on March 17, 2025, delivering on its commercialization timeline and budget.

Read More
image for news Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025
Alpha Cognition Inc. (ACOG) Q1 2025 Earnings Call Transcript
ACOG
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral

Alpha Cognition Inc. (NASDAQ:ACOG ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Henry Du - Interim CFO Michael McFadden - CEO Lauren D'Angelo - COO Conference Call Participants Ram Selvaraju - H.C. Wainwright Michael Freeman - Raymond James Dave Storms - Stonegate Operator Greetings and welcome to the Alpha Cognition earnings call.

Read More
image for news Alpha Cognition Inc. (ACOG) Q1 2025 Earnings Call Transcript
Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates
ACOG
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Negative

Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.75 per share a year ago.

Read More
image for news Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates
Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview
ACOG
Published: May 01, 2025 by: Business Wire
Sentiment: Neutral

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today will announce financial results for the first quarter ended March 31, 2025 on May 15, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-.

Read More
image for news Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview
Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference
ACOG
Published: April 30, 2025 by: Newsfile Corp
Sentiment: Neutral

Grapevine, Texas--(Newsfile Corp. - April 30, 2025) - Alpha Cognition, Inc. (NASDAQ: ACOG), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.

Read More
image for news Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

About Alpha Cognition Inc. Common Stock (ACOG)

  • IPO Date
  • Website https://www.alphacognition.com
  • Industry Financial - Conglomerates
  • CEO Michael E. McFadden
  • Employees 5

Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.